- Ability
to cross blood brain barrier – now confirmed – is significant for possible
treatment of central nervous system diseases
- LXRP
may also be able to deliver micro nicotine doses, as per developing FDA
policies
- LXRP
completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to
better commercialize opportunities
- The
company is a technology disrupter and has applied for new U.S. patent on
its delivery process; it plans to out-license and develop future products
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented
DehydraTECH™ drug delivery platform has been confirmed in analysis of a second
generation lab study on 40 rats to transport 195 percent more nicotine,
reaching peak levels at a four times faster rate to brain tissue than controls
(http://ibn.fm/7RvnA).
Originally, the tests were focused on developing products for nicotine delivery
or smoking alternatives (http://ibn.fm/my45m).
Now, it appears that the technology could also potentially apply to treatment
of nervous system diseases, such as Alzheimer’s.
The blood brain barrier is formed by microvascular
endothelial cells, which form a layer or lining inside blood vessels and exist
to block circulating toxins or other unwanted substances from entering the
brain. It has frustrated medical researchers for years as they’ve
attempted to discover effective methods of transporting beneficial drugs into
the brain.
The new report confirmed first generation results of in vivo
tests on live animals showing that DehydraTECH™ was able to deliver more active
pharmaceutical ingredients (APIs) across the brain’s protective blood brain
barrier, as reported in an article published by the CFN Media Group (http://ibn.fm/rqa7h). Because of
certain similarities in physical structure between the nicotine molecule and
several of the drugs used to treat diseases such as Huntington’s, Parkinson’s,
schizophrenia and depression, it is now theorized that DehydraTECH could offer
similar delivery advantages.
Conceptually, its rapid and efficient delivery to the brain
tissue may allow for smaller micro doses, conforming to newly developing FDA
policies, the company said. Smaller doses could satiate cravings for nicotine
while simultaneously being less addictive, in harmony with FDA goals of reducing
nicotine consumption.
In a news release, Chris Bunka, CEO of LXRP, said,
“Lexaria’s DehydraTECH delivery technology continues to demonstrate its
superior effectiveness in delivering nicotine without the need for combustion
or the need for inhalation whatsoever. Crossing the blood brain barrier is a
significant achievement all on its own and this data confirms the outcome of
our earlier first-generation test.”
The enhanced delivery of nicotine is also significant
because LXRP, through wholly owned subsidiary Lexaria Nicotine Corp., seeks to
encourage cigarette smokers to use nicotine sources that do not contribute to
lung disease. After its original test, LXRP applied to the USPTO for a new
patent. Its IP portfolio already includes patents for oral delivery of
vitamins, NSAIDs and all cannabinoids.
Lexaria has roughly 50 patents pending or awarded and will
license in any of the 40 countries worldwide where its technology already has a
patent or is patent-pending. DehydraTECH™ is its proprietary absorption
technology platform. Based in British Columbia, Canada, LXRP is a biotechnology
company that out-licenses its disruptive delivery technology, which has shown
faster and more effective delivery of cannabinoids and now nicotine.
For more information, visit the company’s website at www.LexariaBioscience.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment